Login to Your Account

AACR 2014

Synthon’s SYD985 outperforms Roche’s Kadcyla, on to phase I

By Nuala Moran
Staff Writer

Friday, April 4, 2014
LONDON – Synthon Biopharmaceuticals NV is making final preparations to advance its lead antibody drug conjugate (ADC) based on Herceptin (trastuzumab) into phase I, after completing a preclinical head-to-head comparison with the Herceptin ADC Kadcyla (ado-trastuzumab emtansine, T-DM1).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription